Shilpa Medicare announces the Third Launch 'IBRUSHIL' for the treatment of Leukemia

After the Successful Launch of Lenvatinib "LENSHIL®" and Dasatinib "DASASHIL®" in India Market, Shilpa Medicare Limited today launches the Indian branded generic uf lbrutinib, an anti-cancer drug w ilh a brand name IBRUSHIL.

IBRUSHIL is available in 140 mg capsules in packs of 30's capsules and 120's capsules.

IBRUSHIL is used to treat patients suffering from Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphomas (MCL) and other related cancers.

This new Leukemia drug is more effective and easier to use. IBRUSHIL attacks cancer cells without damaging normal cells, this causing fewer side effects. The drug is taken once daily, than the standard treatment that requires multiple injections by the patients.

Current, monthly therapy cost of innovator is approximately Rs. 4.36 Lacs, with the launch of IBRUSHIL monthly cost of treatment will be reduced drastically to Rs. 34920/- as monthly therapy cost.

According to the Vision of Shilpa Medicare Limited "Innovating for affordable healthcare" Cancer being a Chronic disease segment where patients need to take therapy for longer time, IBRUSHIL is launched to provide global quality Indian Brand with greater affordability to cancer patients says Mr. Sundeip Bhatia, Business Head Formulations India.

IBRUSHIL will revolutionise the treatment by ensuring to make therapy available for more Indian patients due to increased affordability.

IBRUSHIL (Ibrutinib 140 mg) capsules is being manufactured in the state-of-the-art US-FDA approved manufacturing facility. IBRUSHIL is the same product which was filed with US FDA thus Shilpa is bringing a quality product meeting the world class standards. In 2017, Shilpa filed an abbreviated new drug application (ANDA) with "first to file" status in the US and the same product is being now extended to India.

Today there are around 6,000-10,000 new patients in India who needs Ibrutinib which can be benefited by IBRUSHIL Capsules.

Shares of SHILPA MEDICARE LTD. was last trading in BSE at Rs.367.5 as compared to the previous close of Rs. 375.85. The total number of shares traded during the day was 930 in over 101 trades.

The stock hit an intraday high of Rs. 378 and intraday low of 365.5. The net turnover during the day was Rs. 346643.

Source : Equity Bulls

Keywords